GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Spectranetics Corp (NAS:SPNC) » Definitions » Net-Net Working Capital

The Spectranetics (The Spectranetics) Net-Net Working Capital : $-6.48 (As of Jun. 2017)


View and export this data going back to 1992. Start your Free Trial

What is The Spectranetics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

The Spectranetics's Net-Net Working Capital for the quarter that ended in Jun. 2017 was $-6.48.

The industry rank for The Spectranetics's Net-Net Working Capital or its related term are showing as below:

SPNC's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.445
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

The Spectranetics Net-Net Working Capital Historical Data

The historical data trend for The Spectranetics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Spectranetics Net-Net Working Capital Chart

The Spectranetics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 3.06 -3.72 -5.19 -5.82

The Spectranetics Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.58 -5.68 -5.82 -6.03 -6.48

Competitive Comparison of The Spectranetics's Net-Net Working Capital

For the Medical Devices subindustry, The Spectranetics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Spectranetics's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Spectranetics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where The Spectranetics's Price-to-Net-Net-Working-Capital falls into.



The Spectranetics Net-Net Working Capital Calculation

The Spectranetics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2016 is calculated as

Net-Net Working Capital(A: Dec. 2016 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(57.237+0.75 * 43.565+0.5 * 27.642-355.755
-0-0)/43.3033
=-5.82

The Spectranetics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2017 is calculated as

Net-Net Working Capital(Q: Jun. 2017 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(57.537+0.75 * 47.434+0.5 * 29.565-392.161
-0-0)/43.8965
=-6.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


The Spectranetics  (NAS:SPNC) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


The Spectranetics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of The Spectranetics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


The Spectranetics (The Spectranetics) Business Description

Traded in Other Exchanges
N/A
Address
Spectranetics manufactures and sells single-use medical devices used in minimally invasive cardiovascular procedures. The firm operates in the three categories: vascular intervention, lead management, and laser, service, and other. The vascular intervention business contributes the majority of revenue and sells laser and aspiration catheters, balloon catheters, and support catheters. The lead management business sells devices used to remove pacemaker and defibrillator cardiac leads. The laser, service, and other business includes a laser system for cardiovascular procedures. Spectranetics generates the vast majority of its revenue in the United States.
Executives
Todd C Schermerhorn director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
William C Jennings director 108 CHERRY HILL DRIVE, BEVERLY MA 01915-1053
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Scott William Drake director, officer: President, CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Shahriar Matin officer: Chief Operating Officer 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Stacy Powell Mcmahan officer: CFO 1000 CRANBERRY WOODS DRIVE, CRANBERRY TOWNSHIP PA 16066
Anne Melissa Dowling director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Jonathan Will Mcguire officer: COO 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Stephen D Okland officer: Vice President of Sales 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Martin T Hart director 2401 EAST 2ND AVE., SUITE 250, DENVER CO 80206